UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 27

Sortiert nach

On the magnetic behaviour of heavy Fermion systems

Solid state communications, 1988-02, Vol.65 (6), p.437-439

1988

Volltextzugriff (PDF)

Magnetism and phase-diagram of heavy-fermion compounds

Physica. B, Condensed matter, 1990-08, Vol.165, p.387-388

1990

Volltextzugriff (PDF)

Local-moment and itinerant antiferromagnetism in the heavy-fermion system Ce(Cu1−xNix)2Ge2

Annalen der Physik, 1992, Vol.504 (2), p.78-91

1992

Volltextzugriff (PDF)

Spinfluctuations versus phonons: The case of Heavy-Fermion superconductivity

Annalen der Physik, 1992, Vol.504 (3), p.214-235

1992

Volltextzugriff (PDF)

Spin fluctuations versus phonons: the case of heavy-fermion superconductivity

Annalen der Physik (Leipzig), 1992, Vol.1 (3), p.214-235

1992

Volltextzugriff (PDF)

Local-moment and itinerant antiferromagnetism in the heavy-fermion system Ce(Cu1-xNix)2Ge2

Annalen der Physik (Leipzig), 1992, Vol.1 (2), p.78-91

1992

Volltextzugriff (PDF)

Local‐moment and itinerant antiferromagnetism in the heavy‐fermion system Ce(Cu 1−x Ni x ) 2 Ge 2

Annalen der Physik, 1992-01, Vol.504 (2), p.78-91

1992

Volltextzugriff (PDF)

Effectiveness of a standardized patient education program on therapy-related side effects and unplanned therapy interruptions in oral cancer therapy: a cluster-randomized controlled trial

Supportive care in cancer, 2017-11, Vol.25 (11), p.3475-3483

2017

Volltextzugriff (PDF)

378O Persistence under abemaciclib and endocrine treatment (ABA+ET) in patients with advanced breast cancer (aBC): First results of the randomized IMPACT trial comparing patient coaching with the MASCC oral agent teaching tool (MOATT) versus local routine patient coaching (LC)

Annals of oncology, 2023-10, Vol.34, p.S336-S336

2023

Volltextzugriff (PDF)

P1171: REFLECT: PROSPECTIVE NON‐INTERVENTIONAL STUDY ON THE EFFECTIVENESS AND SAFETY OF SANDOZ RITUXIMAB (SDZ‐RTX) WITH CHOP FOR PATIENTS WITH PREVIOUSLY UNTREATED CD20‐POSITIVE DIFFUSE LARGE B‐CELL LYMPHOMA

HemaSphere, 2022-06, Vol.6 (Suppl), p.1057-1058

2022

Volltextzugriff (PDF)

1853P Real-world evidence of quality of life effects (QoL) of the antiemetic NEPA: Final data in patients receiving oxaliplatin-based chemotherapy within the AkyPRO-trial

Annals of oncology, 2020-09, Vol.31, p.S1061-S1061

2020

Volltextzugriff (PDF)

SANDOZ RITUXIMAB FOR TREATMENT OF DIFFUSE LARGE B‐CELL LYMPHOMA: INTERIM SAFETY RESULTS OF THE NON‐INTERVENTIONAL, OBSERVATIONAL, MULTICENTER, OPEN‐LABEL REFLECT STUDY

Hematological oncology, 2019-06, Vol.37 (S2), p.444-445

2019

Volltextzugriff (PDF)

P636: REAL WORLD OUTCOME WITH IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA FROM THE GERMAN REALITY STUDY

HemaSphere, 2022-06, Vol.6, p.534-535

2022

Volltextzugriff (PDF)

262TiP PROVIDENCE: A prospective, non-interventional study examining real-world clinical and patient-reported outcome (PRO) data in patients (pts) with HER2-positive or HER2-low unresectable or metastatic breast cancer (mBC) treated with trastuzumab deruxtecan

ESMO open, 2024-05, Vol.9, p.103283, Article 103283

2024

Volltextzugriff (PDF)

P-58 Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma: A multi-centric, multi-national, prospective, longitudinal, non-interventional study in Germany and Austria – BERING CRC

Annals of oncology, 2021-07, Vol.32, p.S116

2021

Volltextzugriff (PDF)

Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2− metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial

Annals of oncology, 2023-08, Vol.34 (8), p.660-669

2023

Volltextzugriff (PDF)

P-7 Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal cancer: Update on the first real-world study in Germany and Austria – BERING CRC

Annals of oncology, 2022-06, Vol.33, p.S248

2022

Volltextzugriff (PDF)

680P HANNA: Real-world data of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), including first-line population, treated with nivolumab in Germany

Annals of oncology, 2022-09, Vol.33, p.S854

2022

Volltextzugriff (PDF)

924P HANNA: Effectiveness and quality-of-life data from a real-world study of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with nivolumab in Germany

Annals of oncology, 2021-09, Vol.32, p.S813-S813

2021

Volltextzugriff (PDF)

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings

Annals of oncology, 2013-09, Vol.24 (9), p.2342-2349

2013

Volltextzugriff (PDF)

Abstract P4-14-01: Trastuzumab emtansine improves overall survival versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer: Final results from the phase 3 EMILIA study

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P4-P4-14-01

2016

Volltextzugriff (PDF)

5072 POSTER First-Line Bevacizumab (Bev) Combined With Paclitaxel (pac) in Older Patients (pts) Treated for HER2-Negative Metastatic Breast Cancer (mBC) in a Routine Oncology Practice Study

European journal of cancer (1990), 2011, Vol.47, p.S351-S352

2011

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(27)

Sprache

Englisch
(27)
Japanisch
(2)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

On the magnetic behaviour of heavy Fermion systems

Magnetism and phase-diagram of heavy-fermion compounds

Local-moment and itinerant antiferromagnetism in the heavy-fermion system Ce(Cu1−xNix)2Ge2

Spinfluctuations versus phonons: The case of Heavy-Fermion superconductivity

Spin fluctuations versus phonons: the case of heavy-fermion superconductivity

Local-moment and itinerant antiferromagnetism in the heavy-fermion system Ce(Cu1-xNix)2Ge2

Local‐moment and itinerant antiferromagnetism in the heavy‐fermion system Ce(Cu 1−x Ni x ) 2 Ge 2

Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial

Effectiveness of a standardized patient education program on therapy-related side effects and unplanned therapy interruptions in oral cancer therapy: a cluster-randomized controlled trial

378O Persistence under abemaciclib and endocrine treatment (ABA+ET) in patients with advanced breast cancer (aBC): First results of the randomized IMPACT trial comparing patient coaching with the MASCC oral agent teaching tool (MOATT) versus local routine patient coaching (LC)

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

P1171: REFLECT: PROSPECTIVE NON‐INTERVENTIONAL STUDY ON THE EFFECTIVENESS AND SAFETY OF SANDOZ RITUXIMAB (SDZ‐RTX) WITH CHOP FOR PATIENTS WITH PREVIOUSLY UNTREATED CD20‐POSITIVE DIFFUSE LARGE B‐CELL LYMPHOMA

1853P Real-world evidence of quality of life effects (QoL) of the antiemetic NEPA: Final data in patients receiving oxaliplatin-based chemotherapy within the AkyPRO-trial

SANDOZ RITUXIMAB FOR TREATMENT OF DIFFUSE LARGE B‐CELL LYMPHOMA: INTERIM SAFETY RESULTS OF THE NON‐INTERVENTIONAL, OBSERVATIONAL, MULTICENTER, OPEN‐LABEL REFLECT STUDY

P636: REAL WORLD OUTCOME WITH IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA FROM THE GERMAN REALITY STUDY

927P Patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with nivolumab (NIVO) in the first-line (1L) or later-line (2L+) settings in Germany: Updated results from the real-world HANNA study

262TiP PROVIDENCE: A prospective, non-interventional study examining real-world clinical and patient-reported outcome (PRO) data in patients (pts) with HER2-positive or HER2-low unresectable or metastatic breast cancer (mBC) treated with trastuzumab deruxtecan

P-58 Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma: A multi-centric, multi-national, prospective, longitudinal, non-interventional study in Germany and Austria – BERING CRC

Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2− metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial

P-7 Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal cancer: Update on the first real-world study in Germany and Austria – BERING CRC

680P HANNA: Real-world data of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), including first-line population, treated with nivolumab in Germany

924P HANNA: Effectiveness and quality-of-life data from a real-world study of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with nivolumab in Germany

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings

Abstract P4-14-01: Trastuzumab emtansine improves overall survival versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer: Final results from the phase 3 EMILIA study

5072 POSTER First-Line Bevacizumab (Bev) Combined With Paclitaxel (pac) in Older Patients (pts) Treated for HER2-Negative Metastatic Breast Cancer (mBC) in a Routine Oncology Practice Study

Suchergebnisse filtern